Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

September 16, 2026

Study Completion Date

September 16, 2026

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Iberdomide

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MR

PROCEDURE

Positron Emission Tomography

Undergo PET/CT or PET/MR

DRUG

Teclistamab

Given SC

Trial Locations (9)

23298

RECRUITING

VCU Massey Comprehensive Cancer Center, Richmond

33612

RECRUITING

Moffitt Cancer Center, Tampa

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

85054

RECRUITING

Mayo Clinic Hospital in Arizona, Phoenix

06520

RECRUITING

Yale University, New Haven

06473

RECRUITING

Yale-New Haven Hospital North Haven Medical Center, North Haven

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH